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Abstract: The introduction of the Duke criteria and transesophageal echocardiography has 
improved early recognition of infective endocarditis but patients are still at high risk for severe 
morbidity or death. Whether an exclusively antibiotic regimen is superior to surgical intervention 
is subject to ongoing debate. Current guidelines indicate when surgery is the preferred treat-
ment, but decisions are often based on physician preferences. Surgery has shown to decrease 
the risk of short-term mortality in patients who present with specific symptoms or microorgan-
isms; nevertheless even then it often remains unclear when surgery should be performed. In this 
review we i) systematically reviewed the current literature comparing medical to surgical therapy 
to evaluate if surgery is the preferred option, ii) performed a meta-analysis of studies reporting 
propensity matched analyses, and iii), briefly summarized the current indications for surgery.
Keywords: endocarditis, surgery, antibiotics, review, meta-analysis, propensity analysis, 
mortality, complications
Introduction
Over the last decades infective endocarditis (IE) has been described extensively.1 
This has identified risk factors, clinical features, and predictors of outcome, which led 
to the prescription of antibiotic prophylaxis during the perioperative stage of dental 
and cardiovascular surgery.2,3 Furthermore, the development of the Duke criteria as a 
 diagnostic tool4 and the use of transesophageal echocardiography (TEE) have contrib-
uted significantly to early recognition. Despite these developments, outcomes none-
theless remain unsatisfactory.5–7 Peripheral or cerebrovascular embolisms and acute 
heart failure can cause a drastic decrease of the quality of life. Moreover, mortality 
rates continue to be as high as 50% in some studies.
The usage of an antibiotic regimen alone or in combination with surgical 
intervention is an ongoing debate. Studies investigating the best treatment have shown 
that surgery in combination with antibiotics is superior in some indications.8 The deci-
sion whether and when to treat endocarditis surgically often depends on local practice. 
Uniform recommendations are therefore difficult to make and an overall superiority of 
medical or surgical treatment is not yet established. In a propensity matched analysis, 
surgery seemed to be superior regarding in-hospital mortality,9,10 but at long-term 
follow-up, data suggests no benefit of surgical therapy compared to an exclusively 
medical regimen.11,12 A better outcome with surgical therapy was recently demonstrated 
in the largest reported matched cohorts.13 Still, these studies with propensity matched 
analysis do not produce unambiguous results.14
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Timing of surgery is important. This issue has been 
extensively addressed and there is substantial evidence 
that early surgery can be performed safely, but no con-
sensus exists on the optimal timing of valve replacement 
in the active phase of endocarditis.15,16 Waiting increases 
the risk of stroke or peripheral emboli while early surgery 
increases the risk of procedure-related complications, and 
longer antibiotic treatment can potentially avoid valve 
replacement.
It is clear that the optimal treatment for IE remains 
 challenging. The ongoing ENDOVAL trial will be the first to 
report results of patients treated medically or surgically in a 
randomized fashion and can provide important data.17 Before 
these results will be presented treatment preferences are 
based on current data. This review systematically evaluates 
studies comparing medical to surgical therapy and discusses 
the timing of surgery.
Current data
Systematic review: medical or surgical 
therapy?
We performed a systematic review of studies reporting 
hospital mortality after medical and surgical treatment 
separately. The Medline database, web-of-science, and 
The Cochrane Library were consulted with search entries 
of  “endocarditis” and “treatment or therapy or surgery or 
medical” and  “outcome or survival or mortality or hazard 
ratio” in all  possible combinations. Studies were excluded 
if they focused on a specific aspect of endocarditis, reported 
results of an exclusive patient cohort, or included less than 
50 patients. Multiple studies overlapped in patient popula-
tions; only the study with the largest number of patients 
was included.
Forty eligible studies were identified.9–13,18–52 Data was 
pooled to obtain an overall view of the studied population; 
a total of 11,348 IE episodes were analyzed (Table 1, 
 Figure 1). The largest study on endocarditis to date is from 
the International Collaboration on Endocarditis-Prospective 
Cohort Study (ICE-PCS), which was a prospective, 
multicenter, international registry with 2,781 patients from 
over 50 centers.53 The combined data from the 40 studies had 
similar baseline characteristics for gender, PVE (%), and 
periannular abscess (%). Vegetations were visualized less in 
the combined data (87% compared to 70% in our data). The 
cause of endocarditis was also similar, although the number of 
Staphylococcus aureus infections was 21% in the combined 
series as to 31% in the registry, and viridans streptococci was 
identified in 20% compared to 17% in the ICE-PCS registry. 
Results were remarkably similar; occurrences of stroke and 
non-stroke embolism were almost identical. Furthermore, 
heart failure was diagnosed in 34% compared to 32% in 
ICE-PCS, and in-hospital mortality was 19% versus 18% 
respectively.
One limitation of the ICE-PCS registry is that the indica-
tions for surgery were not reported. In our combined data of 
the 40 studies, surgery was performed in 4,714 episodes of 
endocarditis. Seventeen studies reported indications for sur-
gery; heart failure (49.7%) was the main reason, others were 
large vegetation on echocardiography (21.5%), persistent 
infection (18.8%), embolic complication (17.8%), or abscess 
formation (17.4%). Although it is likely that more complex 
Table 1 Characteristics and outcome of ie in pooled analysis of 
40 systematically included studies
Episodes 
(N = 11,348) (%)
Number of 
studies (N)
Characteristics
   Definite infective endocarditis  
according to Duke criteria
95.4% (33)
 Males 65.5% (39)
  Prosthetic valve endocarditis  
(all studies)
20.2% (39)
  Prosthetic valve endocarditis  
(natural)
21.9% (28)
 Surgery 41.5% (40)
Echocardiographic findings
 Vegetations 69.4% (32)
 Mobile vegetations 51.7% (7)
 New valve regurgitation 47.6% (7)
 Periannular complications 16.2% (4)
 Abscess 12.7% (16)
 Perforation 10.4% (8)
 Prosthetic valve dehiscence 6.9% (12)
Indications for surgery
 Heart failure 49.7% (17)
 emboli 17.8% (16)
 Persistent infection 18.8% (14)
 Abscess 17.4% (12)
 Large vegetation 21.5% (6)
Complications
 emboli
  Brain 14.9% (14)
  Systemic/peripheral 21.2% (21)
    Unspecified 33.0% (9)
 Heart failure 34.1% (34)
 Neurological events 24.0% (7)
 Stroke 16.3% (6)
In-hospital mortality 19.2% (40)
 Surgical treatment 15.8% (40)
 Medical treatment 20.3% (40)
Notes: Prosthetic valve endocarditis “all studies” shows the incidence in all episodes. 
The “natural” occurrence of prosthetic valve endocarditis is the percentage in 
studies  including  all  cases  of  endocarditis,  and  not  studies  specifically  including 
prosthetic or native valve cases.
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Streptococci species
Staphylococcus aureus
Viridans streptococci
Coagulans negative staphylococci
Enterococci species
Fungi
Culture negative21%20%
8%
8%
12%
1%
30%
Figure 1 Causative microorganisms from pooled data of 11,348 ie episodes.
cases of endocarditis underwent surgery, the in-hospital 
mortality was significantly lower in these patients compared 
to those medically treated (15.8% versus 20.3%). This could 
be explained by the fact that patients deemed too high risk 
for surgery due to their condition were treated non-surgically, 
thereby increasing the observed mortality in the medically 
treated patient cohort. As a result of treatment preferences, 
most studies include significant treatment bias and robust 
evidence-based conclusions are unavailable. Predicting 
which treatment is most beneficial for the individual patient 
remains challenging.
Meta-analysis: propensity score studies
A number of studies used propensity matching to compare 
medical to surgical therapy (Table 2).9–14,54 Studies that 
report in-hospital mortality either show results favoring 
surgical therapy over medical therapy or no statistical dif-
ference (Table 2). Combined data reveal an overall odds 
ratio of 0.47 (95% confidence interval [CI] 0.38–0.58) 
supporting surgery. There is however a marked statistically 
significant heterogeneity (I2 = 65%, P = 0.005 (Figure 2)), 
meaning that there is excessive variation in the results. 
Bias
Even though both the pooled and meta-analysis limit bias 
to some extent, included studies that report results after IE 
treatment are inherent to treatment and referral bias.
First of all, studies comparing medical to surgical 
treatment in a randomized fashion are not yet  available. 
Baseline characteristics are therefore incomparable 
between groups. Even with propensity matched analyses, 
patients can only be matched considering the collected 
variables. Characteristics such as frailty are not available 
but can influence outcome. Other certain endocarditis-
specific variables warrant surgical intervention and these 
variables will not be available in the medical group. These T
ab
le
 2
 S
tu
di
es
 r
ep
or
tin
g 
pr
op
en
si
ty
 m
at
ch
ed
 a
na
ly
si
s
Fi
rs
t 
au
th
or
, y
ea
r
Fo
llo
w
-u
p
T
ot
al
 n
o.
 o
f 
pa
ti
en
ts
 (
N
)
M
at
ch
ed
 n
o.
 o
f  
pa
ti
en
ts
 (
N
)
M
ea
n 
ag
e 
 
(y
ea
rs
)
P
ro
st
he
ti
c 
va
lv
e 
en
do
ca
rd
it
is
 (
%
)
M
or
ta
lit
y 
 
su
rg
ic
al
 (
%
)
M
or
ta
lit
y 
 
m
ed
ic
al
 (
%
)
H
az
ar
d 
ra
ti
o/
od
d 
ra
ti
o 
su
rg
er
y 
(9
5%
 C
I)
La
la
ni
, 2
01
0
in
-h
os
pi
ta
l
15
52
61
9:
61
9
53
:5
3
0:
0
11
.8
17
.4
0.
44
 (
0.
33
–0
.5
9)
A
ks
oy
, 2
00
7
in
-h
os
pi
ta
l
42
6
51
:5
1
58
:5
9
18
:2
6
11
.8
21
.6
0.
27
 (
0.
13
–0
.5
5)
w
an
g,
 2
00
5
in
-h
os
pi
ta
l
35
5
68
:6
8
…
10
0:
10
0
22
.1
32
.4
0.
56
 (
0.
23
–1
.3
6)
C
ab
el
l, 
20
09
*
in
-h
os
pi
ta
l
15
16
29
9:
30
0:
29
9:
30
0:
29
9
…
0:
0
N
ot
 r
ep
or
te
d
2.
38
 (
0.
83
–6
.8
8)
0.
49
 (
0.
19
–1
.2
2)
0.
52
 (
0.
23
–1
.1
8)
0.
79
 (
0.
46
–1
.3
5)
0.
21
 (
0.
10
–0
.4
1)
V
ik
ra
m
, 2
00
3
6 
m
on
th
s
51
3
10
9:
10
9
53
:5
5
0:
0
15
28
0.
40
 (
0.
18
–0
.9
1)
T
le
yj
eh
, 2
00
9
6 
m
on
th
s
54
6
93
:9
3
…
…
N
ot
 r
ep
or
te
d
1.
3 
(0
.5
–3
.1
)
Sy
, 2
00
9
M
ed
ia
n 
5.
2 
ye
ar
s
22
3
62
:1
61
47
:5
8
19
:2
6
N
ot
 r
ep
or
te
d
0.
77
 (
0.
42
–1
.4
0)
N
ot
es
: M
ul
tip
le
 v
al
ue
s 
in
 o
ne
 e
nt
ry
 a
re
 li
st
ed
 a
s 
‘s
ur
gi
ca
l p
at
ie
nt
s 
: m
ed
ic
al
 p
at
ie
nt
s’
. *
St
ud
y 
in
 w
hi
ch
 5
 g
ro
up
s 
w
er
e 
m
at
ch
ed
 b
as
ed
 o
n 
th
e 
lik
el
ih
oo
d 
of
 u
nd
er
go
in
g 
su
rg
er
y.
Vascular Health and Risk Management 2011:7submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
258
Head et al
variables can therefore not be matched, and while groups 
are allegedly ‘matched’, they often are not completely. 
A recent study demonstrated that adjustment for an addi-
tional survivor bias factor is needed, as it can significantly 
alter the results.55
Referral bias embodies another bias that is often present 
in the included studies. Patients from the ICE-PCS registry 
transferred to tertiary care centers more frequently under-
went surgery and had higher rates of complications such as 
stroke, heart failure, or valve regurgitation.56 Results from 
certain centers can therefore be skewed in relation to other 
outcomes, and this should be kept in mind when evaluating 
these studies.
The studies included in the meta-analysis have previously 
been shown to be incomparable on multiple fronts.Incon-
sistent results are therefore likely to be not only depend-
able of the given treatment, but also due to used methods 
of data acquirement, co-morbidity definitions, the number 
of variables matched for, reporting of data, and statistical 
methods.57 Furthermore, the deliberate decision whether 
to treat medically or surgically is based on certain specific 
characteristics of the patient, and no study without or with 
propensity analysis can adjust for clinical judgment.
Indications and timing for surgery
In the pooled data, surgery was performed in 41.5% of 
IE cases. Apart from studies comparing medical to surgi-
cal therapy, extensive results of surgical series have been 
described. These studies have furthermore provided data 
on surgical indications and many of these indications have 
now been included in current guidelines.3,58,59
Congestive heart failure
Infective endocarditis often causes heart failure as a result 
of valve regurgitation, or sometimes because of valve 
obstruction or prosthetic valve dehiscence. Heart failure 
is a prognostic factor of impaired survival, independent 
of the causative microorganism or the status of infection. 
Many surgeons consider it as the main indication to perform 
surgery.60
The timing of surgery depends on the progression of 
heart failure. Urgent surgery is needed if acute regurgitation 
of the aortic valve is present. A slower progressive presenta-
tion gives the opportunity to postpone surgery and await the 
effect of medical therapy.
Periannular extension
In native valve endocarditis periannular extension is present 
in 10%–40%, but in prosthetic valve endocarditis (PVE) this 
is as high as 56%–100%.61 Annulus involvement is associ-
ated with development of heart failure and increases mortal-
ity. Surgery is often indicated, especially when an abscess 
is present. The pooled data (Table 1) suggests that this is 
the case in almost 13%, but a recent study focusing exclu-
sively on surgical patients showed a rate of 38%.62 Medical 
therapy is insufficient if an abscess has been detected on 
TEE, and guidelines therefore suggest that these patients 
should undergo surgery.3 If early surgical intervention is not 
performed an abscess can progress into fistulous cavities 
resulting in a mortality rate as high as 41%.63
Periannular extension is likely in case of persistent 
infection despite antibiotic therapy and surgery should be 
considered. An advantage of surgery over an antibiotic 
Cabell 5
Aksoy
Lalani
Cabell 2
Cabell 3
Wang
Cabell 4
Cabell 1
Heterogeneity: I2 = 65%
Test for overall effect: Z = 3.34 (P = 0.0008)
12.8%
12.8%
18.9%
10.0%
11.2%
10.5%
15.1%
8.6%
0.21 [0.10, 0.43]
0.27 [0.13, 0.55]
0.44 [0.33, 0.59]
0.49 [0.20, 1.23]
0.52 [0.23, 1.19]
0.56 [0.23, 1.35]
0.79 [0.46, 1.37]
2.38 [0.83, 6.86]
0.01 0.1 1 10
Favors surgery Favors medical therapy
100
Total (95% Cl) 100.0% 0.50 [0.34, 0.75]
Study or subgroup Weight
Odds  ratio
IV, random, 95% Cl
Odds  ratio
IV, random, 95% Cl
Figure 2 Meta-analysis of studies with propensity analysis.
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regimen is expressed in the completeness of therapy. Open-
heart surgery provides the opportunity to extensively remove 
infected tissue to prevent relapses.
emboli
One of the major complications of IE is the development of 
systemic emboli in 22%–50% of the patients.64,65 Common 
affected sites are the lungs, spleen and peripheral arteries, 
but the most affected (65%) is the central nervous system 
(CNS).65 Not only morbidity is high, but CNS emboli 
 significantly increase the risk of mortality.
The prevention of such events is difficult, since the event 
itself can be the initial presentation of IE. These patients have 
a clear indication for urgent surgery. This however carries an 
increased risk of intracranial hemorrhage while waiting and 
medical therapy increases the risk of  recurrent emboli.  Current 
recommendations therefore suggest a 2–4 week antibiotic 
regimen before surgery can be performed safely. In patients 
who present with transient ischemic attacks or “silent” embo-
lisms early surgery appears safe. No prospective studies have 
confirmed these findings, and more data is needed.66
Large vegetations on TEE are often of prognostic value 
of embolic events. Although there is not a uniform cut-off 
value, vegetations between 10–15 mm are an indication to 
perform urgent surgery.
Persistent sepsis
An ongoing infection despite antibiotic therapy is common 
with aggressive microorganisms, abscess formation, or large 
vegetations. Patients with persistent sepsis are at high risk 
to develop multi-organ failure and guidelines indicate that 
surgery is needed in these patients if cultures persist to be 
positive after 7 days of medical therapy.59,62 Some caution is 
however advised in patients that develop recurrent fever after 
an initially good response to antibiotics, because the fever 
could be explained by other reasons than the endocarditic 
valve. Surgery is only indicated if further diagnostics confirm 
persistent infection of the valve.61
Microorganism
A fungal cause often marks a complex case of IE. First of all, 
the diagnosis is delayed due to recurring negative blood cul-
tures. Once IE is established medical therapy with  antifungals 
is frequently unsatisfactory, resulting in the need for surgery 
in a large percentage of patients. Other indications for surgery 
are large vegetations and periannular extension that regularly 
complicate fungal IE.
Endocarditis caused by bacteria can be challenging as 
well, especially Staphylococcus aureus.67 These complicated 
infections with large vegetations and embolic manifestations 
result in an increased risk of mortality. If multi-resistant 
S aureus is detected, surgery is the only conclusive therapy 
and is always indicated.
Several other micro-organisms such as Brucella, Q 
fever, Pseudomonas aeruginosa, and Staphylococcus 
lugdunensis indicate surgical intervention, but are rare in 
presentation.68–71
Prosthetic Valve endocarditis (PVe)
In approximately 20% of IE a prosthetic valve is involved.72 
A distinction is often made between early and late cases based 
on the time of diagnosis after initial surgery. The prognosis 
of PVE is worse than in native valve IE.72 Several studies 
have compared outcomes after medical and  surgical therapy 
in PVE.14,22,25,33,38,51 A large cohort study of 367 prospectively 
followed patients showed that in-hospital mortality rates were 
similar: 23.4% in medical and 25% in surgical patients.14 Six 
months survival in a different study also showed no favorable 
result for surgery in 80 patients (70% survival in medical 
and 73% in surgical patients).73 Surgery for PVE is often 
indicated, but is a troublesome procedure which is reflected 
in a high recurrent IE rate of up to 15%.74,75
Right-sided endocarditis
The incidence of right-sided IE represents less than 10% of 
all cases of IE.76,77 Right-sided endocarditis mainly occurs 
in patients with intravenous drug use, pacemaker or central 
venous lines, or congenital heart disease. The majority of 
cases involve the tricuspid valve, while isolated pulmonary 
valve endocarditis is rare.78
Isolated right-sided endocarditis has a favorable progno-
sis with low in-hospital mortality and the primary approach 
in these patients should therefore be conservative. Most cases 
respond to medical therapy and surgery is only necessary in 
a small minority of patients.79
The 10 and 20 year survival rate after surgery for iso-
lated right-sided endocarditis has been reported to be 70% 
and 58% respectively, which is better than patients with 
left-sided IE.80
Device-related endocarditis
The use of pacemakers, defibrillators, and other implants has 
grown significantly over the last decades. As a result, endo-
carditis is more frequently associated with these devices.81 
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These types of endocarditis require excision of the infected 
device and complete eradication of the infection. Only 
thereafter can a new device be implanted. Percutaneous 
techniques allow the cardiologist to perform this procedure, 
and surgeon involvement is therefore not necessary.
Risk stratification
Due to the variability in the complexity of IE, the prognosis 
strongly depends on the individual patients’ characteris-
tics. Some patients benefit more from surgery than others, 
and to identify in which group of patients surgery can be 
performed safely and with an adequate result, a recent 
study developed a simplified risk scoring system includ-
ing 13 variables.82 Although this model is noteworthy, one 
should be reminded that data is from the Society of Tho-
racic Surgeons (STS) database in which .19,000 patients 
surgically treated for IE were analyzed to relate baseline 
characteristics to 30-day outcomes. The database only 
includes general characteristics, but endocarditis-specific 
variables such as vegetation size, prosthetic valve endo-
carditis, or periannular extension are lacking. The model 
therefore is similar to the STS score, and is not specific 
for endocarditis. Also, this score is only based on surgical 
patients, and therefore it cannot be used to identify those 
who would benefit most.
Another recent study showed that additive and loga-
rithmic EuroSCORE have a predictive value of 0.84 and 
0.85 respectively, confirming that available risk models 
not specific for endocarditis can be sufficient to predict 
mortality.77
Transcatheter aortic valve 
endocarditis
The introduction of transcatheter aortic valve implantation 
(TAVI) to treat severe aortic stenosis could change the face 
of PVE. The occurrence of early PVE could be influenced 
by the difference between a sternotomy and access through 
the groin. The increased prevalence of paravalvular leakage 
raises concerns because of the associated risk of endocardi-
tis. Little is known about the true incidence of endocarditis 
after TAVI; to date it has only been anecdotally described.83,84 
Follow-up has been short, and late PVE has therefore not 
yet been fully addressed. TAVI has recently shown positive 
results in the PARTNER (Placement of Aortic Transcatheter 
Valves) trial,85 and more randomized trials will start enroll-
ment soon to broaden the indication to lower risk patients.86 
Further data will contribute to the unknown prevalence of 
endocarditis after TAVI.
New insights
Late in 2011 the first randomized data from the ENDOVAL 
trial on surgical or medical treatment for IE will be  available. 
The trial will only include high-risk patients with 1) periannular 
complications, 2) new onset aortic-ventricular block, 3) new 
onset severe valve regurgitation, 4) early-onset PVE, or 5) 
Staphylococcus aureus endocarditis. The trial will likely lead 
to treatment preferences for most endocarditis patients. Too 
high-risk patients with an EuroSCORE . 40% or an emergent/
urgent indication for surgery because of heart failure due to 
valvular insufficiency, fungal endocarditis, or septic shock are 
excluded.17 It is these patients that lead  treatment bias when 
comparing studies from different  centers. Some surgeons are 
willing to operate on the very high-risk patients, while oth-
ers are reticent. To evaluate the need for surgery in high risk 
patients, another trial in high-risk patients is preferable.The 
ENDOVAL trial is the first trial assessing the use of early sur-
gery in endocarditis, and could stimulate others to follow.
Conclusions
Endocarditis has been extensively described over the last 
decades and treatment with surgery is established for certain 
indications associated with improved survival. Surgical treat-
ment of PVE carries quite a high mortality and requires close 
follow-up due to a continued postoperative risk.The selection of 
patients who benefit most from valve replacement is becoming 
more transparent, but treatment often remains biased because 
of surgeon preferences. A large number of ongoing studies and 
randomized trials will produce stronger evidence.
Author disclosures
The authors have no conflicts of interest to declare.
References
1. Cabell CH, Abrutyn E. Progress towards a global understanding of infective 
endocarditis. Early lessons from the International Collaboration on Endo-
carditis investigation. Infect Dis Clin North Am. 2002;16(2): 255–272.
2. Wilson W, Taubert KA, Gewitz M, et al. Prevention of infective endo-
carditis: guidelines from the American Heart Association: a guideline 
from the American Heart Association Rheumatic Fever, Endocarditis 
and Kawasaki Disease Committee, Council on Cardiovascular Disease 
in the Young, and the Council on Clinical Cardiology, Council on 
Cardiovascular Surgery and Anesthesia, and the Quality of Care and 
Outcomes Research Interdisciplinary Working Group. Circulation. 2007; 
116(5):1736–1754.
3. Bonow RO, Carabello BA, Chatterjee K, et al. 2008 Focused update 
incorporated into the ACC/AHA 2006 guidelines for the management 
of patients with valvular heart disease: a report of the American  College 
of Cardiology/American Heart Association Task Force on Practice 
Guidelines (Writing Committee to Revise the 1998 Guidelines for 
the Management of Patients With Valvular Heart Disease): endorsed 
by the Society of Cardiovascular Anesthesiologists, Society for 
 Cardiovascular Angiography and Interventions, and the Society of Tho-
racic Surgeons. Circulation. 2008;118(15):e523–e661.
Vascular Health and Risk Management 2011:7 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
261
Surgery for endocarditis
 4. Durack DT, Lukes AS, Bright DK. New criteria for diagnosis of infective 
endocarditis: utilization of specific echocardiographic findings. Duke 
Endocarditis Service. Am J Med. 1994;96(3):200–209.
 5. Heiro M, Helenius H, Mäkilä S, et al. Infective endocarditis in a Finnish 
teaching hospital: a study on 326 episodes treated during 1980–2004. 
Heart. 2006;92(10):1457–1462.
 6. Durante-Mangoni E, Bradley S, Selton-Suty C, et al. Current features 
of infective endocarditis in elderly patients: results of the International 
Collaboration on Endocarditis Prospective Cohort Study. Arch Intern 
Med. 2008;168(19):2095–2103.
 7. Mansur AJ, Dal Bó CM, Fukushima JT, Issa VS, Grinberg M, 
 Pomerantzeff PM. Relapses, recurrences, valve replacements, and 
mortality during the longterm follow-up after infective endocarditis. 
Am Heart J. 2001;141(1):78–86.
 8. Yu VL, Fang GD, Keys TF, et al. Prosthetic valve endocarditis: 
 superiority of surgical valve replacement versus medical therapy alone. 
Ann Thorac Surg. 1994;58(4):1073–1077.
 9. Cabell CH, Abrutyn E, Fowler VG Jr, et al. Use of surgery in 
patients with native valve infective endocarditis: results from the 
 International Collaboration on Endocarditis Merged Database. Am 
Heart J.2005;150(5):1092–1098.
 10. Aksoy O, Sexton DJ, Wang A, et al. Early Surgery in Patients with 
Infective Endocarditis: A Propensity Score Analysis. Clin Infect Dis. 
2007;44(3):364–372.
 11. Tleyjeh IM, Ghomrawi HM, Steckelberg JM, et al. The impact of 
valve surgery on 6-month mortality in left-sided infective endocarditis. 
 Circulation. 2007;115(13):1721–1728.
 12. Sy RW, Bannon PG, Bayfield MS, Brown C, Kritharides L. Survivor 
treatment selection bias and outcomes research: a case study of surgery 
in infective endocarditis. Circ Cardiovasc Qual Outcomes. 2009;2(5): 
469–474.
 13. Lalani T, Cabell CH, Benjamin DK, et al. Analysis of the impact 
of early surgery on in-hospital mortality of native valve endocardi-
tis: use of propensity score and instrumental variable methods 
to adjust for treatment-selection bias. Circulation. 2010;121(8): 
1005–1013.
 14. Wang A, Pappas P, Anstrom KJ, et al. The use and effect of  surgical 
therapy for prosthetic valve infective endocarditis: a propensity  analysis 
of a multicenter, international cohort. Am Heart J. 2005;150(5): 
1086–1091.
 15. Bogers AJ, van Vreeswijk H, Verbaan CJ, et al. Early surgery for 
active infective endocarditis improves early and late results. Thorac 
Cardiovasc Surg. 1991;39(5):284–288.
 16. Thuny F, Beurtheret S, Mancini J, et al. The timing of surgery influence 
mortality and morbidity in adults with severe complicated infective 
endocarditis: a propensity analysis. Eur Heart J. 2009; doi:10.1093/
eurheartj/ehp089.
 17. San Román JA, López J, Revilla A, et al. Rationale, design, and 
methods for the early surgery in infective endocarditis study 
(ENDOVAL 1): a multicenter, prospective, randomized trial com-
paring the state-of-the-art therapeutic strategy versus early sur-
gery strategy in infective endocarditis. Am Heart J. 2008;156(3): 
431–436.
 18. Tornos MP, Olona M, Permanyer-Miralda G, Almirante B, 
 Evangelista A, Soler-Soler J. Is the clinical spectrum and prognosis 
of native valve infective endocarditis in non-addicts changing? Eur 
Heart J. 1995; 16(11):1686–1691.
 19. Schulz R, Werner GS, Fuchs JB, et al. Clinical outcome and echocar-
diographic findings of native and prosthetic valve endocarditis in the 
1990’s. Eur Heart J. 1996;17(2):281–288.
 20. Sandre RM, Shafran SD. Infective endocarditis: review of 135 cases 
over 9 years. Clin Infect Dis. 1996;22(2):276–286.
 21. Olaison L, Hogevik H, Myken P, Oden A, Alestig K. Early surgery in 
infective endocarditis. QJM. 1996;89(4):267–278.
 22. Tornos P, Almirante B, Olona M, et al. Clinical outcome and long-term 
prognosis of late prosthetic valve endocarditis: a 20-year experience. 
Clin Infect Dis. 1997;24(3):381–386.
 23. Hricak V, Kovacik J, Marx P, et al. Etiology and risk factors of 180 cases 
of native valve endocarditis. Report from a 5-year national prospective 
survey in Slovak Republic. Diagn Microbiol Infect Dis. 1998;31(3): 
431–435.
 24. Castillo JC, Anguita MP, Ramírez A, et al. Long term outcome of 
infective endocarditis in patients who were not drug addicts: a 10 year 
study. Heart. 2000;83(5):525–530.
 25. Gordon SM, Serkey JM, Longworth DL, Lytle BW, Cosgrove DM 3rd. 
Early onset prosthetic valve endocarditis: the Cleveland Clinic experi-
ence 1992–1997. Ann Thorac Surg. 2000;69(5):1388–1392.
 26. Bishara J, Leibovici L, Gartman-Israel D, et al. Long-term outcome of 
infective endocarditis: the impact of early surgical intervention. Clin 
Infect Dis. 2001;33(10):1636–1643.
 27. Wallace SM, Walton BI, Kharbanda RK, Hardy R, Wilson AP, 
 Swanton RH. Mortality from infective endocarditis: clinical predictors 
of outcome. Heart. 2002;88(1):53–60.
 28. Mouly S, Ruimy R, Launay R, et al. The changing clinical aspects of 
infective endocarditis: descriptive review of 90 episodes in a French 
teaching hospital and risk factors for death. J Infect. 2002;45(4): 
246–256.
 29. Hoen B, Alla F, Selton-Suty C, et al. Changing Profile of Infective 
Endocarditis: Results of a 1-Year Survey in France. JAMA. 2002;288(1): 
75–81.
 30. Pachirat O, Chetchotisakd P, Klungboonkrong V, Taweesangsuksakul P, 
Tantisirin C, Loapiboon M. Infective endocarditis: prevalence, char-
acteristics and mortality in Khon Kaen, 1990–1999. J Med Adoc Thai. 
2002;85(1):1–10.
 31. Di Salvo G, Thuny F, Rosenberg V, et al. Endocarditis in the elderly: 
clinical, echocardiographic, and prognostic features. Eur Heart J. 
2003;24(17):1576–1583.
 32. Ako J, Ikari Y, Hatori M, Hara K, Ouchi Y. Changing spectrum of 
infective endocarditis: review of 194 episodes over 20 years. Circ J. 
2003;67(1):3–7.
 33. Akowuah EF, Davies W, Oliver S, et al. Prosthetic valve endocarditis: 
early and late outcome following medical or surgical treatment. Heart. 
2003;89(3):269–272.
 34. Krcmery V, Gogová M, Ondrusová A, et al. Etiology and risk factors 
of 339 cases of infective endocarditis: report from a 10-year national 
prospective survey in the SLovak Republic. J Chemother. 2003; 
15(6):579–583.
 35. Mourvillier B, Trouillet JL, Timsit JF, et al. Infective endocarditis 
in the intensive care unit: clinical spectrum and prognostic factors in 
228 consecutive patients. Intensive Care Med. 2004;30(11): 
2046–2052.
 36. Zamorano J, de Isla LP, Moura L, et al. Impact of echocardiography in 
the short- and long-term prognosis of patients with infective endo-
carditis and negative blood cultures. J Heart Valve Dis. 2004;13(6): 
997–1004.
 37. Cecchi E, Forno D, Imazio M, et al. New trends in the epidemiological 
and clinical features of infective endocarditis: results of a multicenter 
prospective study. Ital Heart J. 2004;5(4):249–256.
 38. Habib G, Tribouilloy C, Thuny F, et al. Prosthetic valve endocarditis: 
who needs surgery? A multicentre study of 104 cases. Heart. 2005; 
91(7):954–959.
 39. Garg N, Kandpal B, Garg N, et al. Characteristics of infective endo-
carditis in a developing country-clinical profile and outcome in 192 
Indian patients, 1992–2001. Int J Cardiol. 2005;98(2):253–260.
 40. Tornos P, Iung B, Permanyer-Miralda G, et al. Infective endocarditis 
in Europe: lessons from the Euro heart survey. Heart. 2005;91(5): 
571–575.
 41. Ferreiros E, Nacinovich F, Casabé JH, et al. Epidemiologic, clinical, and 
microbiologic profile of infective endocarditis in Argentina: a national 
survey. The Endocarditis Infecciosa en la República Argentina-2 
(EIRA-2) Study. Am Heart J. 2006;151(2):545–552.
 42. Leblebicioglu H, Yilmaz H, Tasova Y, et al. Characteristics and analysis 
of risk factors for mortality in infective endocarditis. Eur J Epidemiol. 
2006;21(1):25–31.
Vascular Health and Risk Management 2011:7submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
262
Head et al
 43. Abramczuk E, Hryniewiecki T, Stepin´ska J. Influence of pathogenetic 
factors on prognosis in patients with native valve infective endocarditis. 
Kardiol Pol. 2006;64(7):675–681.
 44. Slater MS, Komanapalli CB, Tripathy U, Ravichandran PS, 
 Ungerleider RM. Treatment of endocarditis: a decade of experience. 
Ann Thorac Surg. 2007;83(6):2074–2079.
 45. Delahaye F, Alla F, Béguinot I, et al. In-hospital mortality of infective 
endocarditis: prognostic factors and evolution over an 8-year period. 
Scand J Infect Dis. 2007;39(10):849–857.
 46. Heiro M, Helenius H, Hurme S, et al. Short-term and one-year 
outcome of infective endocarditis in adult patients treated in a 
Finnish teaching hospital during 1980–2004. BMC Infect Dis. 
2007;7:78.
 47. Krecki R, Drozdz J, Ibata G, et al. Clinical profile, prognosis and 
 treatment of patients with infective endocarditis; a 14-year follow-up 
study. Pol Arch Med Wewn. 2007;117(11–12):512–520.
 48. Trabelsi I, Rekik S, Znazen A, et al. Native valve infective endocarditis 
in a tertiary care center in a developing country (Tunisia). Am J Cardiol. 
2008;102(9):1247–1251.
 49. Pazdernik M, Baddour LM, Pelouch R. Infective endocarditis in the 
Czech Republic: eight years of experience at one of the country’s largest 
medical centers. J Heart Valve Dis. 2009;18(4):395–400.
 50. Nunes MC, Gelape CL, Ferrari TC. Profile of infective endocarditis at 
a tertiary care center in Brazil during a seven-year period:  prognostic 
 factors and in-hospital outcome. Int J Infect Dis. 2010;14(5): 
e394–e398.
 51. Alonso-Valle H, Fariñas-Alvarez C, García-Palomo JD, et al.  Clinical 
course and predictors of death in prosthetic valve endocarditis 
over a 20-year period. J Thorac Cardiovasc Surg. 2010;139(4): 
887–893.
 52. López J, Revilla A, Vilacosta I, et al. Age-dependent profile of left-
sided infective endocarditis: a 3-center experience. Circulation. 2010; 
121(7):892–897.
 53. Murdoch DR, Corey GR, Hoen B, et al. Clinical presentation, 
 etiology, and outcome of infective endocarditis in the 21st century: the 
 International Collaboration on Endocarditis-Prospective Cohort Study. 
Arch Intern Med. 2009;169(5):463–473.
 54. Vikram HR, Buenconsejo J, Hasbun R, Quagliarello VJ. Impact 
of valve surgery on 6-month mortality in adults with complicated, 
left-sided native valve endocarditis: a propensity analysis. JAMA. 
2003;290(24):3207–3214.
 55. Tleyjeh IM, Ghomrawi HM, Steckelberg JM, et al. Conclusion about 
the association between valve surgery and mortality in an infective 
endocarditis cohort changed after adjusting for survivor bias. J Clin 
Epidemiol. 2010;63(2):130–135.
 56. Kanafani ZA, Kanj SS, Cabell CH, et al. Revisiting the effect of referral 
bias on the clinical spectrum of infective endocarditis in adults. Eur J 
Clin Microbiol Infect Dis. 2010;29(10):1203–1210.
 57. Tleyjeh IM, Kashour T, Zimmerman V, Steckelberg JM, 
Wilson WR, Baddour LM. The role of valve surgery in infective 
endocarditis  management: a systematic review of observational  studies 
that included propensity score analysis. Am Heart J. 2008;156(5): 
901–909.
 58. Habib G, Hoen B, Tornos P, et al. Guidelines on the prevention, 
 diagnosis, and treatment of infective endocarditis (new version 2009): 
the Task Force on the Prevention, Diagnosis, and Treatment of Infective 
Endocarditis of the European Society of Cardiology (ESC). Eur Heart J. 
2009;30(19):2369–2413.
 59. Baddour LM, Wilson WR, Bayer AS, et al. Infective endocarditis: 
 diagnosis, antimicrobial therapy, and management of  complications: 
a statement for healthcare professionals from the Committee on 
 Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on 
Cardiovascular Disease in the Young, and the Councils on Clinical Car-
diology, Stroke, and Cardiovascular Surgery and Anesthesia,  American 
Heart Association: endorsed by the Infectious Diseases Society of 
America. Circulation. 2005;111(23):e395–e434.
 60. Revilla A, López J, Villacosta I, et al. Clinical and prognostic profile 
of patients with infective endocarditis who need urgent surgery. Eur 
Heart J. 2007;28(1):65–71.
 61. Prendergast BD, Tornos P. Surgery for infective endocarditis: who and 
when? Circulation. 2010;121(9):1141–1152.
 62. Klieverik LM, Yacoub MH, Edwards S, et al. Surgical treatment of 
active native aortic valve endocarditis with allografts and mechanical 
prostheses. Ann Thorac Surg. 2009;88(6):1814–1821.
 63. Anguera I, Miro JM, Vilacosta I, et al. Aorto-cavitary fistulous tract 
formation in infective endocarditis: clinical and echocardiographic 
features of 76 cases and risk factors for mortality. Eur Heart J. 2005; 
26(3):288–297.
 64. Thuny F, Di Salvo G, Belliard O, et al. Risk of embolism and death 
in infective endocarditis: prognostic value of echocardiography: 
a prospective multicenter. Circulation. 2005;112(1):69–75.
 65. Heiro M, Nikoskelainen J, Engblom E, Kotilainen E, Marttila R, 
Kotilainen P. Neurologic manifestations of infective endocarditis: a 
17 year experience in a teaching hospital in Finland. Arch Intern Med. 
2000;160(18):2781–2787.
 66. Derex L, Bonnefoy E, Delahaye F. Impact of stroke on therapeutic deci-
sion making in infective endocarditis. J Neurol. 2010;257:315–321.
 67. Remadi JP, Habib G, Nadji G, et al. Predictors of death and impact of 
surgery in Staphylococcus aureus infective endocarditis. Ann Thorac 
Surg. 2007;83(4):1295–1302.
 68. Morpeth S, Murdoch D, Cabell CH, et al. Non-HACEK gram-negative 
bacillus endocarditis. Ann Intern Med. 2007;147(12):829–835.
 69. Raoult D, Marrie T. Q Fever. Clin Infect Dis. 1995;20(3):489–495.
 70. Jacobs F, Abramowicz D, Vereerstraeten P, Le Clerc JL, Zech F, 
Thys JP. Brucella endocarditis: the role of combined medical and 
surgical treatment. Rev Infect Dis. 1990;12(5):740–744.
 71. Anguera I, Del Río A, Miró JM, et al. Staphylococcus lugdunensis 
 infective endocarditis: description of 10 cases and analysis of native 
valve, prosthetic valve, and pacemaker lead endocarditis clinical 
 profiles. Heart. 2005;91(2):e10.
 72. Wang A, Athan E, Pappas PA, et al. Contemporary clinical profile 
and outcome of prosthetic valve endocarditis. JAMA. 2007;297(12): 
1354–1361.
 73. Hill EE, Herregods MC, Vanderschueren S, Claus P, Peetermans WE, 
Herijgers P. Management of prosthetic valve infective endocarditis. 
Am J Cardiol. 2008;101(8):1174–1178.
 74. Lytle BW, Priest BP, Taylor PC, et al. Surgical treatment of prosthetic 
valve endocarditis. J Thorac Cardiovasc Surg. 1996;111(1):198–207.
 75. Pansini S, di Summa M, Patane F, Forsenatti PG, Serra M, Del Ponte S. 
Risk of recurrence after reoperation for prosthetic valve endocarditis. 
J Heart Valve Dis. 1997;6(1):84–87.
 76. Mylonakis E, Calderwood SB. Infective endocarditis in adults. N Engl 
J Med. 2001;345(18):1318–1330.
 77. Mokhles MM, Ciampichetti I, Head SJ, Takkenberg JJM, Bogers AJJC. 
Survival of surgically treated infective endocarditis: a comparison with 
the general Dutch population. Ann Thorac Surg. 2011; doi:10.1016/j.
athoracsur. 2011.02.007.
 78. Nishida K, Fukuyama O, Nakamura DS. Pulmonary valve endocarditis 
caused by right ventricular outflow obstruction in association with sinus 
of valsalva aneurysm: a case report. J Cardiothorac Surg. 2008;3:46.
 79. Hecht SR, Berger M. Right-sided endocarditis in intravenous drug users.
Prognostic features in 102 episodes. Ann Intern Med. 1992;117(7): 
560–566.
 80. Musci M, Siniawski H, Pasic M, Grauhan O, Weng Y, Meyer R, et al. 
Surgical treatment of right-sided active infective endocarditis with or 
without involvement of the left heart: 20-year single center experience. 
Eur J Cardiothor Surg. 2007;32:118–125.
 81. Baddour LM, Bettmann MA, Bolger AF, et al. Nonvalvular cardiovascu-
lar device related infections. Circulation. 2003;108(16):2015–2031.
 82. Gaca JG, Sheng S, Daneshmand MA, et al. Outcomes for endocarditis 
surgery in North America: a simplified risk scoring system. J Thorac 
Cardiovasc Surg. 2011;141(1):98–106.
Vascular Health and Risk Management
Publish your work in this journal
Submit your manuscript here: http://www.dovepress.com/vascular-health-and-risk-management-journal
Vascular Health and Risk Management is an international, peer-
reviewed journal of therapeutics and risk management, focusing on 
concise rapid reporting of clinical studies on the processes involved 
in the maintenance of vascular health; the monitoring, prevention and 
treatment of vascular disease and its sequelae; and the involvement of 
metabolic disorders, particularly diabetes. This journal is indexed on 
PubMed Central and MedLine. The manuscript management system 
is completely online and includes a very quick and fair peer-review 
system, which is all easy to use. Visit http://www.dovepress.com/ 
testimonials.php to read real quotes from published authors.
Vascular Health and Risk Management 2011:7 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
Dovepress
263
Surgery for endocarditis
 85. Leon MB, Smith CR, Mack M, et al. Transcatheter aortic-valve 
implantation for aortic stenosis in patients who cannot undergo surgery. 
N Engl J Med. 2010;363(17):1597–1607.
 86. Head SJ, Kappetein AP. Transcatheter aortic valve implantation after 
PARTNER: what is up next? Euro Intervention. 2010;6(5):560–561.
 83. Piazza N, Marra S, Webb J, et al. Two cases of aneurysm of the 
anterior mitral valve leaflet associated with transcatheter aortic valve 
endocarditis: a mere coincidence? J Thorac Cardiovasc Surg. 2010; 
140(3):e36–e38.
 84. Head SJ, Dewey TM, Mack MJ. Fungal endocarditis after  transfemoral 
aortic valve implantation. Catheter Cardiovasc Interv. 2011; doi: 
10.1002/ccd.23038.
